Associated Papers
POLE Mutation Associated With Microsatellite Instability and High Tumor Mutational Burden Confers Exquisite Sensitivity to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer: A Case Report and Genomic Database Analysis.
Lara MS et al.
Clinical Lung Cancer, 2025
An Analysis of Genetic Polymorphisms in 76 Genes Related to the Development of Ovarian Tumors of Different Aggressiveness.
Szafron LA et al.
International Journal of Molecular Sciences, 2024
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L et al.
Frontiers in Oncology, 2023
Custom multi‑tumor next‑generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three‑year clinical use.
Chevrier S et al.
International Journal of Molecular Medicine, 2022
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
Spatially interacting phosphorylation sites and mutations in cancer.
Huang KL et al.
Nature Communications, 2021
Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
Rotow JK et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2020
Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan-cancer analysis.
Liu H et al.
Cancer Communications (london, England), 2020
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
Epidermal growth factor receptor somatic mutation analysis in 354 Chinese patients with non-small cell lung cancer.
Quan X et al.
Oncology Letters, 2018
Spectrum of EGFR gene mutations in Vietnamese patients with non-small cell lung cancer.
Vu HA et al.
Asia-pacific Journal of Clinical Oncology, 2016
ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics.
Alaoui-Jamali MA et al.
Frontiers in Genetics, 2015
[Experience on epidermal growth factor receptor gene mutation analysis in non-small cell lung cancer].
Zhang J et al.
Zhonghua Bing Li Xue Za Zhi = Chinese Journal of Pathology, 2011
Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study.
Boldrini L et al.
Oncology Reports, 2009